Streetbeat News

Analyst Ratings

ORCL

Goldman Sachs analyst Kash Rangan maintains a Neutral rating on Oracle (NYSE:ORCL) and raises the price target from $75 to $120.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 1:08 pm

CFLT

Guggenheim analyst Howard Ma downgraded Confluent (NASDAQ:CFLT) from Buy to Neutral.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 1:07 pm

LOGI

Citigroup analyst Asiya Merchant has downgraded Logitech International (NASDAQ:LOGI) from Buy to Neutral and announced a $70 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 1:06 pm

MGY

Goldman Sachs analyst Umang Choudhary maintains a Buy rating on Magnolia Oil & Gas (NYSE:MGY) but lowers the price target from $27.5 to $24.5.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 1:05 pm

AMAT

Needham analyst Quinn Bolton downgrades Applied Mat (NASDAQ:AMAT) from Buy to Hold.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 1:04 pm

APA

Goldman Sachs analyst Neil Mehta maintains a Neutral rating on APA Corporation (NASDAQ:APA) and lowers the price target from $40 to $35.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 1:03 pm

SGH

Over the past 3 months, 5 analysts have published their opinion on SMART Global Holdings (NASDAQ:SGH) stock, with 4 bullish and 1 somewhat bullish. The average 12-month price target is $29.8, with a high of $35.00 and a low of $25.00. The average price target has increased by 22.48% over the past month.

Portfolio Pulse from Benzinga Insights

June 14, 2023 | 1:02 pm

WEN

In the last quarter, Wendy's (NASDAQ:WEN) received 2 bullish, 1 somewhat bullish, and 3 indifferent ratings from 6 analysts. The average 12-month price target is $25.17, up 0.68% from the previous average of $25.00.

Portfolio Pulse from Benzinga Insights

June 14, 2023 | 1:02 pm

SPGI

S&P Global (NYSE:SPGI) has received 7 somewhat bullish analyst ratings in the last quarter, with an average price target of $411.86, implying an upside compared to the current price of $390.56. The average price target has increased by 2.35% over the past month.

Portfolio Pulse from Benzinga Insights

June 14, 2023 | 1:01 pm

BPMC

Analysts have provided various ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter, with an average price target of $73.0 compared to its current price of $58.3. The average price target has increased by 25.65% over the past month.

Portfolio Pulse from Benzinga Insights

June 14, 2023 | 1:01 pm